Posterior-Inferior Intra-articular Cortical Piercing Titanium Implant for Sacroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes (PIERCE)
Posterior-Inferior Intra-articular Cortical PiERcing Titanium Implant for SaCroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes
The purpose of this study is to evaluate outcomes in patients treated with iFuse INTRA Ti for chronic SI joint pain.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
PIERCE is a prospective, multicenter, post-market observational study evaluating the safety, performance, and efficacy of iFuse INTRA Ti.
Studietype
Studietype
Registrering (Antatt)
Registrering
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Director of Clinical Affairs
- Telefonnummer: 408-207-0700
- E-post: clinicalaffairs.@si-bone.com
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with sacroiliac joint (SIJ) dysfunction due to degenerative sacroiliitis or sacroiliac joint disruption for at least 6 months refractory to non-surgical care
Beskrivelse
Inclusion Criteria:
- Age > 21 years.
- Patient has chronic lower back pain (≥6 months) refractory to non-surgical care.
- Diagnosis of sacroiliac joint dysfunction (degenerative sacroiliitis or SIJ disruption) and scheduled to be treated with INTRA Ti.
- Patient has SIJ pain of at least 5 on a 0-10 numeric rating scale (NRS) prior to procedure.
- Participant has signed study-specific informed consent form.
Exclusion Criteria:
- ASA score 4 or 5.
- Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture.
- Other known sacroiliac pathology such as: inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy), tumor, infection, acute fracture.
- Current diagnosis of cluneal neuralgia.
- Previous SIJ implant placement, including allograft, on the treated (index) side.
- Anatomic anomalies/defects that would preclude safe and/or biomechanically acceptable device placement.
- History of recent (<1 year) major trauma to pelvis.
- Previously diagnosed or suspected severe osteoporosis (defined as prior T-score < -2.5 or history of osteoporotic fracture).
- Chronic rheumatologic condition (e.g., rheumatoid arthritis).
- Current diagnosis of fibromyalgia.
- Known allergy to titanium or titanium alloys.
- Current local or systemic infection that raises the risk of surgery.
- Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation.
- Currently pregnant or planning pregnancy in the next 2 years (self-reported).
- Patient is a prisoner or a ward of the state.
- Known or suspected active drug or alcohol abuse, including opioids
- Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
SIJ Dysfunction treated with INTRA Ti
Patients with sacroiliac joint (SIJ) dysfunction due to various causes refractory to non-surgical management. |
FDA-cleared implant used for fusion of the sacroiliac joint (SIJ) for SIJ dysfunction, that is a direct result of SIJ disruption and degenerative sacroiliitis. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite endpoint of safety and performance
Tidsramme: 6 months.
|
The participant is considered a success if all the following criteria are met:
|
6 months.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants with a Serious Adverse Event (SAE)
Tidsramme: 24 months
|
Proportion of participants with a serious adverse event classified as probably or definitely related to the study device or procedure |
24 months
|
|
Proportion of Participants with ≥1 Subsequent Surgical Intervention(s) (SSI)
Tidsramme: 24 months
|
Proportion of participants undergoing one or more SSI related to the index procedure. |
24 months
|
|
Proportion of Treated Sides with Radiographic Evidence of Loosening
Tidsramme: 24 months
|
Proportion of treated sides showing signs of loosening of INTRA Ti, as evidenced by both radiolucent areas around implant plus bony reaction ("rind") near implant. |
24 months
|
|
Proportion of Implants with Radiographic Evidence of Device Migration.
Tidsramme: 24 months
|
Proportion of INTRA Ti implants that show evidence of device migration. |
24 months
|
|
Proportion of Implants with Radiographic Evidence of Device Breakage.
Tidsramme: 24 months
|
Proportion of INTRA Ti implants that show breakage. |
24 months
|
|
Proportion of Participants with Radiographic Evidence of Fusion
Tidsramme: 24 months
|
Bony apposition to the implant at 12 months as evaluated by pelvic CT |
24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Stacie Tran, MPH, SI-BONE
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
Andre studie-ID-numre
- 303256
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
There are currently no plans to share but IPD may be shared with qualified researchers upon reasonable request, subject to sponsor approval and data use agreements.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .